NDLI: Plasma and CSF Benzodiazepine Receptor Ligand Concentrations in Cirrhotic Patients with Hepatic Encephalopathy: Relationship to Severity of Encephalopathy and to Pharmaceutical Benzodiazepine Intake

Please wait, while we are loading the content...

Plasma and CSF Benzodiazepine Receptor Ligand Concentrations in Cirrhotic Patients with Hepatic Encephalopathy: Relationship to Severity of Encephalopathy and to Pharmaceutical Benzodiazepine Intake

DNA Fragmentation and HSP72 Gene Expression by Adenovirus-Mediated Gene Transfer in Postischemic Gerbil Hippocampus and Ventricle

Thiamine Deficiency-Induced Disruptions in the Diurnal Rhythm and Regulation of Body Temperature in the Rat

Improvement of Chronic Hepatic Encephalopathy in Dogs by the Benzodiazepine-Receptor Partial Inverse Agonist Sarmazenil, but Not by the Antagonist Flumazenil

Differential Effects of Facial Nerve Transection on Heat Shock Protein 70 Expression in the Developing and Adult Hamster Facial Nucleus

Announcements ( Metabolic Brain Disease , Volume 13 , Issue 3 )

Metabolic Brain Disease : Volume 13, Issue 2, June 1998

Metabolic Brain Disease : Volume 13, Issue 1, March 1998

Metabolic Brain Disease : Volume 12

Plasma and CSF Benzodiazepine Receptor Ligand Concentrations in Cirrhotic Patients with Hepatic Encephalopathy: Relationship to Severity of Encephalopathy and to Pharmaceutical Benzodiazepine Intake

Content Provider	Springer Nature Link
Author	Perney, Pascal Butterworth, Roger F. Mousseau, Darrell D. Lavoie, Joel Fabbro Peray, Pascale Blanc, François Layrargues, Gilles Pomier
Copyright Year	1998
Abstract	Increased plasma and CSF concentrations of substances which bind to brain benzodiazepine receptors have previously been reported in cirrhotic patients with hepatic encephalopathy (HE). However, their relationship to previous intake of pharmaceutical benzodiazepines has not been clearly established. In the present study, plasma levels of benzodiazepine receptor ligands (BZRLs) were measured using a sensitive radioreceptor assay in 12 control subjects with no evidence of hepatic, neurological or psychiatric illness, 11 cirrhotic patients without HE, 24 cirrhotic patients with moderate (grade I-II) HE and in 45 cirrhotic patients with severe (grade II-IV) HE. In addition, CSF concentrations of BZRLs were measured in 8 cirrhotic patients with HE and an equal number of age-matched controls. Recent intake (within 10 days) of pharmaceutical benzodiazepines was assessed by detailed review of medical files, and interviews with the patient, at least one family member as well as the pharmacist. Significantly increased plasma concentrations of BZRLs were observed in cirrhotic patients with severe encephalopathy (p<0.02) compared to controls and to cirrhotic patients without (or with mild) neurological impairment. Increased plasma BZRLs could be accounted for by prior exposure to benzodiazepine medication in all cases. CSF concentrations of BZRLs in cirrhotic patients were not significantly different from control values. These findings do not support a role for “endogenous” benzodiazepines in the pathogenesis of HE in chronic liver disease but suggest that pharmaceutic benzodiazepines administered to cirrhotic patients as sedatives or as part of endoscopic work-up could have contributed to the neurological impairment in some patients.
Starting Page	201
Ending Page	210
Page Count	10
File Format	PDF
ISSN	08857490
Journal	Metabolic Brain Disease
Volume Number	13
Issue Number	3
e-ISSN	15737365
Language	English
Publisher	Kluwer Academic Publishers-Plenum Publishers
Publisher Date	1998-01-01
Publisher Place	New York
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Neurosciences Neurology Oncology Biochemistry
Content Type	Text
Resource Type	Article
Subject	Biochemistry Neurology (clinical) Cellular and Molecular Neuroscience

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Increased Brain Concentrations of Endogenous (Non-benzodiazepine) GABA-A Receptor Ligands in Human Hepatic Encephalopathy

Natural endogenous ligands for benzodiazepine receptors in hepatic encephalopathy

Study on the Sternberg Paradigm in Cirrhotic Patients Without Overt Hepatic Encephalopathy

Visual event-related potentials in cirrhotic patients without overt encephalopathy

Visual Event-Related Potentials in Cirrhotic Patients without Overt Encephalopathy

RNA oxidation and zinc in hepatic encephalopathy and hyperammonemia

A patients’ and caregivers’ perspective on hepatic encephalopathy

Reversibility of hepatic encephalopathy after liver transplantation

Improvement of Chronic Hepatic Encephalopathy in Dogs by the Benzodiazepine-Receptor Partial Inverse Agonist Sarmazenil, but Not by the Antagonist Flumazenil

Plasma and CSF Benzodiazepine Receptor Ligand Concentrations in Cirrhotic Patients with Hepatic Encephalopathy: Relationship to Severity of Encephalopathy and to Pharmaceutical Benzodiazepine Intake

Similar Documents

Increased Brain Concentrations of Endogenous (Non-benzodiazepine) GABA-A Receptor Ligands in Human Hepatic Encephalopathy

Natural endogenous ligands for benzodiazepine receptors in hepatic encephalopathy

Study on the Sternberg Paradigm in Cirrhotic Patients Without Overt Hepatic Encephalopathy

Visual event-related potentials in cirrhotic patients without overt encephalopathy

Visual Event-Related Potentials in Cirrhotic Patients without Overt Encephalopathy

RNA oxidation and zinc in hepatic encephalopathy and hyperammonemia

A patients’ and caregivers’ perspective on hepatic encephalopathy

Reversibility of hepatic encephalopathy after liver transplantation

Improvement of Chronic Hepatic Encephalopathy in Dogs by the Benzodiazepine-Receptor Partial Inverse Agonist Sarmazenil, but Not by the Antagonist Flumazenil

Plasma and CSF Benzodiazepine Receptor Ligand Concentrations in Cirrhotic Patients with Hepatic Encephalopathy: Relationship to Severity of Encephalopathy and to Pharmaceutical Benzodiazepine Intake